At a Glance
- Company: Ironwood Pharmaceuticals, Inc.
- Location: Boston, Massachusetts, US
- Headline figures: 2026 revenue guidance $450–475m; adjusted EBITDA >$300m
- Focus area: Gastrointestinal and rare diseases, led by LINZESS and apraglutide
- Next steps: Launch confirmatory phase 3 apraglutide trial; continue strategic review
What happened?
The Pharma Letter reports that Ironwood Pharmaceuticals’ share price climbed sharply after the company reaffirmed its 2025 outlook and issued much stronger‑than‑expected financial guidance for 2026. The update, delivered via a New Year press release, signals accelerating growth in US LINZESS sales, higher total revenue and a step‑change in profitability, which collectively boosted investor sentiment.
Why does it matter?
For 2026, Ironwood projects LINZESS US net sales of – billion dollars, up from 2025 guidance of –million dollars, alongside total revenue of 450-475 million dollars. Adjusted EBITDA is expected to exceed 300 million dollars in 2026—more than double the 2025 target of over 135 million dollars—supporting debt covenant compliance and giving the company more financial flexibility.
Who’s behind it?
Ironwood is a gastrointestinal and rare diseases specialist whose main revenue driver is LINZESS (linaclotide), partnered with AbbVie in the US. The company is led by chief executive Tom McCourt, who highlighted 2025 progress in maximising LINZESS, strengthening the balance sheet and keeping open “strategic alternatives” to enhance shareholder value.
How was it achieved?
Management lowered LINZESS’s list price effective 1 January 2026 to respond to shifting US pricing dynamics, particularly inflation‑linked statutory rebates, while still expecting higher net sales because rebate inflation components fall away. Combined with low‑single‑digit demand growth, this pricing reset, plus disciplined cost control, underpins the forecast jump in total revenue and adjusted EBITDA for 2026.
What’s next?
Ironwood is maintaining its 2025 guidance—LINZESS US net sales of -890 million dollars, total revenue of 290–million dollars, and adjusted EBITDA of more than 135 million dollars—while indicating it is on track to hit the low end of those ranges. The company also plans to initiate a confirmatory phase 3 trial of apraglutide for short bowel syndrome with intestinal failure in the first half of 2026 and continues to review strategic options, which could include partnerships or corporate transactions.
What are people saying?
CEO Tom McCourt said the 2026 guidance “demonstrates the significant progress” made in maximising LINZESS and delivering sustained profits and cash flows, positioning Ironwood to drive shareholder value. Market commentary notes that shares have rebounded after previous setbacks around apraglutide and earlier revenue forecasts, with the new outlook seen as a reset that restores credibility to management’s growth story.